A collaboration to use real-world diagnostics evidence will seek to answer key questions about the novel coronavirus, including epidemiologic patterns, individual risk factors, and characteristics of immunity that might develop after infection with COVID-19. 
 
The Diagnostics Evidence Accelerator is a joint project between the Reagan-Udall Foundation for the Food and Drug Administration and the nonprofit Friends of Cancer Research; more than 50 collaborators were initially involved in laying out the scope and depth of work that Accelerator participants are seeking to accomplish. Participants in the Diagnostics Evidence Accelerator include device manufacturers, technology companies, researchers from the academic and public sectors, professional societies, payers and health systems, said the Foundation in announcing the Accelerator’s launch.

Read more